Showing 3511-3520 of 5231 results for "".
- National Rosacea Society Awards New Grants; Call for 2018 Proposalshttps://practicaldermatology.com/news/national-rosacea-society-awards-new-grants/2458008/The National Rosacea Society (NRS) awarded funding for three new studies, in addition to continuing support for three ongoing studies, as part of its research grants program. Dr. Benjamin Kaffenberger, MD assistant professor of dermatology at the Ohio
- James P. Hartman Named New Vice President and General Manager at Solta Medicalhttps://practicaldermatology.com/news/james-p-hartman-named-new-vice-president-and-general-manager-at-solta-medical/2458011/James P. Hartman is the new Vice President and general manager at Solta Medical, a division of Valeant Pharmaceuticals North America LLC. Mr. Hartman joined Solta Medical from Merz Aesthetics (a division of Merz Pharm
- Two New Grants Continue Dr. Fredric S. Brandt's Legacyhttps://practicaldermatology.com/news/two-new-grants-continue-dr-fredric-s-brandts-legacy/2458018/Two American Society for Dermatologic Surgery members received grants totaling more tha
- Novan Has Guidance Meeting with FDA on SB204https://practicaldermatology.com/news/novan-has-guidance-meeting-with-fda-on-sb204/2458040/Novan, Inc. is eyeing an additional pivotal trial for its investigational treatment for acne vulgaris, SB204. The company concluded a guidance meeting with the FDA regarding SB204 in which the agency advised that an additional pivotal trial should be conducted. Given the need for the ad
- Dove: Women's Shower Routines May Do More Harm Than Goodhttps://practicaldermatology.com/news/dove-womens-shower-routines-may-do-more-harm-than-good/2458043/Close to 80 percent of dermatologists believe women often focus on facial skincare, but neglect body skincare, according to new research from Dove. What’s more, 69 percent of dermatologists report that many women use gentle facial c
- Dr. Michael H. Gold Joins AIVITA Scientific Advisory Boardhttps://practicaldermatology.com/news/dr-michael-h-gold-joins-aivita-scientific-advisory-board/2458042/Nashville dermatologist Michael H. Gold, MD, has joined AIVITA Biomedical’s Scientific Advisory Board. His addition comes as AIVITA prepares to launch its upcoming ROOT OF SKINTM line of rejuvenating skincare products. Dr. Gold,
- Eva Genel Named Director of Research and Development, Skincare at Silk Therapeuticshttps://practicaldermatology.com/news/eva-genel-named-director-of-research-and-development-skincare-at-silk-therapeutics/2458047/Eva Genel is the new Director of Research and Development, Skincare at Silk Therapeutics Inc., a specialty biomaterials company. In this new role, Genel's key responsibilities include designing and assessing clean, skincare formulations, o
- Two Galderma Rosacea Therapies Work Well Togetherhttps://practicaldermatology.com/news/two-galderma-rosacea-therapies-work-well-together/2458061/Combined use of Galderma’s SOOLANTRA (ivermectin1% Cream) and Mirvaso (Brimonidine 0.33% Gel) pack a one-two punch against the erythema and inflammatory lesions of rosacea, the MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCe
- Galderma Names New Managers of Prescription Business and Aesthetic & Corrective Business Units; Dr. Kelly Huang to Obalonhttps://practicaldermatology.com/news/alisa-lask-to-oversee-galdermas-aesthetic-corrective-business-unit-dr-kelly-huang-to-obalon/2458064/Galdmera has named new managers of its Prescription Business and Aesthetic & Corrective Business units in the United States. Chris Chapman is Galderma’s new Vice President and General Manager of Prescription Business and Alisa Lask <
- GBI Research: Global Dermatology Pipeline Will See Shift Toward Increased Use of Biologicshttps://practicaldermatology.com/news/gbi-research-global-dermatology-pipeline-to-see-shift-toward-increased-use-of-biologics/2458071/The global dermatology pipeline, which currently comprises 850 products with a disclosed stage of development, is primarily made up of drugs at an early stage of development, with the late stages of the pipeline dominated by generics and biosimilars, according to GBI Research. The company